Announcements Trials

Browse Landscape

Phase

Status

Completed 86 Terminated 28 Unknown 10 Recruiting 8 Withdrawn 6 Active not recruiting 3 Suspended 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Drug Therapy 107 Cisplatin 97 Radiotherapy 89 Carboplatin 87 Bevacizumab 79 Oxaliplatin 74 tislelizumab 68 Capecitabine 68 Gemcitabine 64 Cyclophosphamide 64 toripalimab 62 Paclitaxel 57 pembrolizumab 55 sintilimab 53 Specimen Handling 53 Surgical Procedures, Operative 52 anlotinib 49 Fluorouracil 49 Magnetic Resonance Spectroscopy 48 Immune Checkpoint Inhibitors 43 Blood Specimen Collection 42 130-nm albumin-bound paclitaxel 42 Standard of Care 38 camrelizumab 36 fludarabine 35 lenvatinib 34 Leucovorin 34 venetoclax 30 Radiosurgery 30 Immunotherapy 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × OTHER × Mitoxantrone × Clear all

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡